C18orf21

Across TCGA pan-cancer cohorts, C18orf21 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C18orf21 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher C18orf21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C18orf21 expression acts as an unfavorable survival marker.

STAD, LUSC, and KIRC are the cancer types where C18orf21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.677	.004	12	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	9	view →
KIRC	OS	Median	All	0.232	0.630	.046	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C18orf21–STAD (OS)

Open the STAD breakdown →